February 21, 2017 / 2:26 PM / in 10 months

BRIEF-Oncogenex Pharmaceuticals says clinical data from trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated

Feb 21 (Reuters) - Oncogenex Pharmaceuticals Inc:

* Oncogenex Pharmaceuticals, Inc. announces phase 2 apatorsen data for two clinical trials presented at the American Society Of Clinical Oncology (asco) 2017 genitourinary cancers symposium

* Oncogenex Pharmaceuticals Inc- clinical data from trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below